Publications by authors named "Michael J Foley"
Article Synopsis
- The ORBITA-2 trial examined the effectiveness of percutaneous coronary intervention (PCI) in relieving stable angina in patients with coronary artery disease (CAD) compared to a placebo.
- Participants reported daily angina episodes and underwent tests to measure fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) before being randomized to receive either PCI or a placebo.
- Results indicated that lower FFR and iFR values were associated with significantly greater improvement in angina symptoms following PCI, suggesting these measurements can help predict the benefits of the intervention.
Background: Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many patients. The reason for this was unclear.
Objectives: This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, noninvasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI.
Background: In stable coronary artery disease, 30% to 60% of patients remain symptomatic despite successful revascularization. Perhaps not all symptoms reported by a patient with myocardial ischemia are, in fact, angina.
Objectives: This study sought to determine whether independent symptom verification using a placebo-controlled ischemic stimulus could distinguish which patients achieve greatest symptom relief from percutaneous coronary intervention (PCI).
Background: The coronary sinus reducer (CSR) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion. We aimed to measure its efficacy, compared with placebo, on myocardial ischaemia reduction and symptom improvement.
Methods: ORBITA-COSMIC was a double-blind, randomised, placebo-controlled trial conducted at six UK hospitals.
The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. Whilst placebo-controlled data show an improvement in angina, these results are unreplicated and are the subject of further confirmatory research. The mechanism of action of this unintuitive therapy is unknown.
View Article and Find Full Text PDFArticle Synopsis
- A study was done to see if a procedure called PCI helps people with stable angina (chest pain) feel better than a fake (placebo) procedure.
- 301 patients were divided into two groups: one had the PCI and the other had the fake procedure for 12 weeks.
- The results showed that those who had PCI had better scores for their angina symptoms, meaning they felt less pain compared to the placebo group.
Computer Simulation and Optimization of Cranial Vault Distraction.
Cleft Palate Craniofac J
March 2018
Objective: The objective of this study was to validate the proof of concept of a computer-simulated cranial distraction, demonstrating accurate shape and end volume.
Design: Detailed modeling was performed on pre- and postoperative computed tomographic (CT) scans to generate accurate measurements of intracranial volume. Additionally, digital distraction simulations were performed on the preoperative scan and the resultant intracranial volume and shape were evaluated.
To determine if droperidol i.v. is as effective as prochlorperazine i.
View Article and Find Full Text PDF